Home > > > > > Report Detail

Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Name :
Date: 30-Aug-2022
No. of pages: 112
Inquire Before Buying

Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Drugs In Development, 2022, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.

Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 7, 7, 1, 8 and 4 respectively.

Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).

- The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bronchiectasis - Overview
Bronchiectasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Bronchiectasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchiectasis - Companies Involved in Therapeutics Development
Bronchiectasis - Drug Profiles
Bronchiectasis - Dormant Projects
Bronchiectasis - Discontinued Products
Bronchiectasis - Product Development Milestones
Featured News & Press Releases
May 17, 2022: Insmed presents new data on brensocatib at American Thoracic Society 2022 International Conference
Apr 07, 2022: Renovion provides regulatory update and initiation of clinical program in non-CF bronchiectasis
Feb 22, 2022: Armata Pharmaceuticals announces clearance of investigational new drug application to initiate phase 2 clinical trial of AP-PA02 in non-cystic fibrosis bronchiectasis
Sep 21, 2021: Renovion and the COPD Foundation launch COPD and bronchiectasis development partnership to address unmet patient need
Dec 02, 2020: Insmed announces initiation of phase 3 ASPEN study of brensocatib in patients with bronchiectasis
Nov 15, 2020: SolAeroMed provides update on Phase II trial of S1226
Nov 13, 2020: Insmed receives priority medicines (PRIME) designation from European Medicines Agency (EMA) for Brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE)
Sep 30, 2020: Insmed highlights progress across portfolio and outlines growth strategy on brensocatib at R&D Day
Sep 07, 2020: New England Journal of Medicine publishes positive results from phase 2 WILLOW study of Brensocatib in patients with non-cystic fibrosis bronchiectasis
Jun 24, 2020: Positive Results from phase 2 WILLOW study of Brensocatib in patients with non-cystic fibrosis bronchiectasis presented at ATS Virtual Clinical Trials Session
Jun 08, 2020: Insmed receives FDA breakthrough therapy designation for Brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE)
May 20, 2020: Insmed to showcase new brensocatib data at American Thoracic Society virtual clinical trials session
Feb 03, 2020: Insmed announces positive top-line results from phase 2 WILLOW study of INS1007 in patients with Non-Cystic Fibrosis Bronchiectasis
Jun 07, 2019: Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference
Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bronchiectasis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Bronchiectasis - Dormant Projects, 2022
Bronchiectasis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Bronchiectasis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
  • Global Carbocisteine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 102
    According to our LPI (LP Information) latest study, the global Carbocisteine market size was valued at US$ 55 million in 2023. With growing demand in downstream market, the Carbocisteine is forecast to a readjusted size of US$ 76 million by 2030 with a CAGR of 4.9% during review period. The research report highlights the growth potential of the global Carbocisteine market. Carbocisteine are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • Global Bovine Respiratory Disease Treatment Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 120
    Report Overview: Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired host immunity, inadequate housing conditions, and environmental factors. The major factor leading to bovine respiratory diseases are host factors, environmental factors, and direct influence of infectious agents such as virus, bacteria, and parasites. However, due to increasing consumption of milk and beef products, the need for......
  • Global Ambroxol Market Research Report 2023
    Published: 01-Dec-2023        Price: US 2900 Onwards        Pages: 91
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Ambroxol market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Teva - Bayer - Novartis - Mylan - Bidachem - Hanmi - Hexal Pharma - Sris Pharmaceuticals - Hubei Ocean Biotechnology - DM Pharma......
  • Global Carbocisteine Professional Survey Report 2023, Forecast to 2028
    Published: 23-Nov-2023        Price: US 3280 Onwards        Pages: 101
    Carbocisteine is a type of medicine called a mucolytic. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to de......
  • Global Carbocisteine Market Research Report 2023, Forecast to 2028
    Published: 23-Nov-2023        Price: US 2680 Onwards        Pages: 136
    Carbocisteine is a type of medicine called a mucolytic. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to de......
  • Global Bovine Respiratory Disease Treatment Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 09-Nov-2023        Price: US 3380 Onwards        Pages: 99
    Market Overview of Global Bovine Respiratory Disease Treatment market: According to our latest research, the global Bovine Respiratory Disease Treatment market looks promising in the next 5 years. As of 2022, the global Bovine Respiratory Disease Treatment market was estimated at USD 1748.69 million, and it's anticipated to reach USD 2423.79 million in 2028, with a CAGR of 5.59% during the forecast years. Bovine respiratory disease (BRD) is a multifactorial and complex diseas......
  • Respiratory Collaboration and Licensing Deals 2016-2023
    Published: 01-Oct-2023        Price: US 3995 Onwards        Pages: 200
    Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of respiratory deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. Understanding......
  • Global Drugs For Respiratory Syncytial Virus (Rsv) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Sep-2023        Price: US 3380 Onwards        Pages: 106
    Market Overview of Global Drugs For Respiratory Syncytial Virus (Rsv) market: According to our latest research, the global Drugs For Respiratory Syncytial Virus (Rsv) market looks promising in the next 5 years. As of 2022, the global Drugs For Respiratory Syncytial Virus (Rsv) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and......
  • Global Ambroxol Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Sep-2023        Price: US 3380 Onwards        Pages: 127
    Market Overview of Global Ambroxol market: According to our latest research, the global Ambroxol market looks promising in the next 5 years. As of 2022, the global Ambroxol market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Ambroxol market, with a systematical descriptio......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs